DaVita vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
US kidney care leader with ~3,000 dialysis centers; $12.8B FY2024 revenue; 237,000 US patients 3x/week; Berkshire Hathaway ~40% stake; GLP-1 drugs may reduce ESRD prevalence long-term.
About
DaVita Inc. is the leading kidney care company in the United States, providing dialysis services to patients with chronic kidney failure and end-stage renal disease (ESRD), founded in 1994 as Total Renal Care and rebranded as DaVita in 2000 after acquiring Gambro Healthcare. Headquartered in Denver, Colorado and trading on NYSE (DVA), DaVita generated approximately $12.8 billion in revenues for FY2024 under CEO Javier Rodriguez, operating approximately 3,000 outpatient dialysis centers across the United States serving approximately 237,000 patients, plus international operations in 13 countries. Berkshire Hathaway holds approximately 40% of DaVita's common shares—a major Warren Buffett investment thesis built on the essential, recurring nature of ESRD treatment, which patients require three times per week for life unless they receive a kidney transplant.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.